Report for: Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial

Title	Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial
Published by	Springer Nature, November 2017
DOI	10.1186/s13063-017-2234-7
Pubmed ID	29132404
Authors	Geoff Bellingan, David Brealey, Jordi Mancebo, Alain Mercat, Nicolò Patroniti, Ville Pettilä, Michael Quintel, Jean-Louis Vincent, Mikael Maksimow, Markku Jalkanen, Ilse Piippo, V. Marco Ranieri

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
Finland	1	50%
Unknown	1	50%

Type	Count	As %
Members of the public	1	50%
Practitioners (doctors, other healthcare professionals)	1	50%

Mendeley readers

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	101	100%

Readers by professional status	Count	As %
Researcher	17	17%
Student > Bachelor	12	12%
Student > Master	12	12%
Other	10	10%
Student > Ph. D. Student	10	10%
Other	7	7%
Unknown	33	33%

Readers by discipline	Count	As %
Medicine and Dentistry	37	37%
Nursing and Health Professions	12	12%
Pharmacology, Toxicology and Pharmaceutical Science	5	5%
Psychology	3	3%
Biochemistry, Genetics and Molecular Biology	2	2%
Other	5	5%
Unknown	37	37%

Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute…